DEFA14A: ESSA Pharma Amends Merger Terms, Increases Contingent Liabilities

ESSA Pharma Inc. has amended its business combination agreement, increasing the contingent value right component and contingent reserve due to new potential liabilities, while maintaining the expected upfront cash payment.

Summary

• ESSA Pharma Inc. (ESSA) has amended its business combination agreement with XenoTherapeutics, Inc., Xeno Acquisition Corp., and XOMA Royalty Corporation (XRC) through an amendment dated September 23, 2025.
• The amendment maintains the expected cash payment to shareholders at approximately US$0.12 per Common Share at closing, after accounting for a prior distribution of approximately US$1.6910318 per Common Share paid on August 22, 2025.
• The contingent value right (CVR) component has been restructured and increased, with each non-transferable CVR now representing the right to receive up to approximately US$0.14 per CVR.
• The total potential CVR consideration has increased to US$7,450,000, comprising up to US$3,800,000 for Company Litigation, up to US$3,500,000 for Potential Contingent Claim Liability, and up to US$150,000 for Legacy Liability, less a CVR Retention Amount not exceeding US$750,000.
• The Contingent Reserve, held for potential liabilities, has doubled from US$3,700,000 to US$7,450,000.
• The Target Closing Net Cash has decreased from US$90,000,000 to US$85,250,000, accounting for an additional US$1,000,000 in potential costs.
• These changes are primarily driven by a 'Due Bill Matter' arising from incorrect public disclosures on August 14 and August 25, 2025, regarding the due bill trading period on Nasdaq, which led to a trading halt and potential contingent claims.
• The Special Meeting for Securityholders to vote on the Arrangement has been adjourned from September 10, 2025, to October 3, 2025.
• Leerink Partners, who previously rendered a fairness opinion on the original cash amount, was not requested to, and did not, render an opinion on the fairness of the financial terms as modified by the Amendment.

Sentiment

Score: 3

Explanation: The significant increase in contingent liabilities and the contingent reserve, coupled with a reduction in overall net cash and the introduction of a new, specific litigation risk, indicate a materially less favorable outcome for shareholders. The non-transferable nature of the CVR and the absence of a renewed fairness opinion on the amended terms further contribute to a negative sentiment, despite the board's stated belief in the deal's best interest.

Positives

• The Board believes the Amendment is in the best interests of the Company and Shareholders, considering the benefits of closing the transaction versus pursuing liquidation, and the associated risks and costs.
• The CVR Consideration provides an opportunity for Securityholders to receive additional proceeds from resolved litigation and liabilities, with a potential maximum payout of up to US$0.14 per CVR.
• The Amendment is seen as a fair and equitable way to allocate risks for potential contingent liabilities arising from the Due Bill Matter.

Negatives

• The Contingent Reserve, which holds funds for potential liabilities, has doubled from US$3,700,000 to US$7,450,000, indicating a larger portion of the company's value is now subject to future uncertainties.
• The Target Closing Net Cash has decreased from US$90,000,000 to US$85,250,000, reflecting a reduction in the overall cash pool available to the company, including an additional US$1,000,000 in potential costs.
• A new 'Potential Contingent Claim Liability' of up to US$3,500,000 has been explicitly introduced, stemming from incorrect public disclosures regarding due bill trading, adding a new and significant layer of risk and potential expense.
• Leerink Partners, the financial advisor, did not provide a fairness opinion on the financial terms of the Arrangement as modified by the Amendment, which could raise concerns about the revised deal's fairness to shareholders.
• The CVRs are non-transferable, limiting liquidity for shareholders who might prefer immediate cash or tradable assets.

Risks

• Holders of CVRs may never receive any proceeds if costs and expenses related to Company Litigation or Potential Contingent Claim Liability exceed the maximum CVR amount (US$7,450,000).
• The Purchaser and the Company may be targets of securities class action and derivative lawsuits, including those related to the Potential Contingent Claim Liability, which could result in substantial costs and divert management time.
• Litigation could delay or prevent the Arrangement from being completed.
• Disruptions from the Transaction could harm the Company's business, current plans, and operations.
• The Company's ability to retain and hire key personnel may be impacted.
• Potential adverse reactions or changes to business relationships could result from the announcement or completion of the Transaction.
• Unpredictability and severity of catastrophic events (e.g., acts of terrorism, pandemics, war) could affect the Company's business.
• Significant transaction costs are associated with the Arrangement.
• The Transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the Transaction could arise.
• General business, market, and economic conditions could impact the Company.
• Certain restrictions during the pendency of the Transaction may limit the Company's ability to pursue business opportunities or strategic transactions.
• Potential exposure or liability relating to the Due Bill Matter.

Future Outlook

The Company anticipates the completion of the Transaction on the amended terms, subject to securityholder, regulatory, and court approvals. The CVRs offer potential future payments contingent on the resolution of specified litigation and liabilities within defined periods. The Special Meeting is scheduled for October 3, 2025, to vote on the Arrangement and, if not approved, on the Company's voluntary liquidation and dissolution. ESSA intends to apply to the British Columbia Supreme Court for an order varying the Interim Order, including setting the Special Meeting date, dissent rights deadline (October 1, 2025), and Final Order hearing date (October 7, 2025).

Management Comments

• "Under the Amendment, based on the estimates of ESSA’s management, ESSA shareholders are expected to receive approximately US$0.12 per Common Share at closing plus one non-transferable contingent value right (CVR) per Common Share, which now represents the right to receive up to approximately US$0.14 per CVR and payable within specified periods following the close of the Transaction as described herein."
• "The Transaction Committee unanimously and after careful consideration determined that the Amendment is in the best interests of the Company and the Company’s Shareholders, and unanimously recommended to the Board that it approve the Amendment."
• "All members of the Board (other than Mr. Parkinson, who had recused himself from the meeting) unanimously concluded that the Amendment was in the best interests of the Company and the Company’s Shareholders and approved the Amendment and authorized its submission to the Securityholders."

Industry Context

NA

Corporate Governance

Legal Proceedings

• Company Litigation: Litigation against the Company and its directors or officers currently active or arising within 18 months following closing of the Arrangement, with up to US$3,800,000 allocated from CVR proceeds.
• Potential Contingent Claim Liability: Any proceeding against or involving the Company and its directors and/or officers arising from the Company's public disclosures on August 14, 2025, and August 25, 2025, regarding the due bill trading period, with up to US$3,500,000 allocated from CVR proceeds.
• Securities class action and derivative lawsuits: Potential lawsuits against the Purchaser or the Company related to the Arrangement, which could result in substantial costs and divert management time.
• Third-party claims: Attempts to bring claims against the Purchaser or the Company seeking to restrain the Arrangement or seeking monetary compensation or other redress.

Related Party Transactions

• David Parkinson, a director, declared he would be receiving a collateral benefit in the Transaction within the meaning of Multilateral Instrument 61-101 and recused himself from the Board meeting where the Amendment was approved.

Stakeholder Impact

• Shareholders: Will receive an expected US$0.12 per share in cash at closing and a non-transferable CVR with uncertain future value (up to approx. US$0.14 per CVR), subject to litigation outcomes and expenses. The overall value proposition has shifted more towards contingent, uncertain payments.
• Company: Faces increased contingent liabilities and legal expenses related to the 'Due Bill Matter' and other litigation, impacting the net cash available at closing and requiring a larger contingent reserve.
• Management: Time and resources may be diverted to defend against potential lawsuits and manage the contingent liabilities, potentially impacting operational focus.
• Purchaser (XRC): Benefits from a larger contingent reserve to cover potential liabilities, mitigating some of its risk exposure related to the Due Bill Matter and other litigation.

Next Steps

• Securityholders are urged to submit proxies for the Special Meeting if they have not already done so.
• The Special Meeting will be held virtually on October 3, 2025, to consider and vote on the Arrangement Resolution, advisory compensation resolution, and, if the Arrangement fails, resolutions for voluntary liquidation and dissolution.
• ESSA intends to apply to the British Columbia Supreme Court for an order varying the Interim Order, including setting the Special Meeting date, dissent rights deadline (October 1, 2025), and Final Order hearing date (October 7, 2025).
• CVR payments for Company Litigation Proceeds, Potential Contingent Claim Liability Proceeds, and Legacy Liability Proceeds will be made within specified periods following the closing of the Transaction and resolution of the respective liabilities.

Key Dates

Recommendation

The amendment significantly increases the contingent liabilities and the contingent reserve, shifting more of the deal's value into uncertain, non-transferable Contingent Value Rights (CVRs). While the upfront cash payment per share remains consistent with the net expected amount after the prior distribution, the overall deal structure has become less favorable due to increased risk and reduced certainty of future payouts. The absence of a renewed fairness opinion on the amended terms further compounds this uncertainty. A seasoned investor would likely view this as a deterioration of the original deal's value proposition and would consider selling to mitigate exposure to these increased risks and uncertainties.

Keywords

ESSA Pharma, XenoTherapeutics, XOMA Royalty Corporation, Merger, Acquisition, Business Combination, SEC Filing, Proxy Statement, Contingent Value Right, CVR, Due Bill, Nasdaq, Litigation, Shareholder Vote, Special Meeting, Financial Amendment, Corporate Governance, Risk Factors